<DOC>
	<DOCNO>NCT00232102</DOCNO>
	<brief_summary>This study do evaluate long-term safety tegaserod woman symptoms dyspepsia complete core study . Tegaserod evaluate 6 mg twice daily .</brief_summary>
	<brief_title>Extension Study Assess Long-Term Safety Tegaserod Women With Symptoms Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Female , 18 year old Fulfilled eligibility criterion CHTF919 D2302 ( double blind study ) successfully complete doubleblind study Early discontinuation doubleblind study Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Dyspepsia , gastrointestinal , tegaserod</keyword>
</DOC>